Needham & Company LLC Issues Positive Forecast for Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price

Arcutis Biotherapeutics (NASDAQ:ARQT) had its target price raised by Needham & Company LLC from $31.00 to $36.00 in a report issued on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

ARQT has been the subject of a number of other research reports. The Goldman Sachs Group increased their price objective on shares of Arcutis Biotherapeutics from $19.00 to $29.00 and gave the company a “neutral” rating in a research note on Thursday, October 30th. HC Wainwright raised their price target on shares of Arcutis Biotherapeutics from $30.00 to $34.00 and gave the stock a “buy” rating in a research note on Thursday. Mizuho lifted their price objective on Arcutis Biotherapeutics from $32.00 to $37.00 and gave the company an “outperform” rating in a report on Friday, November 28th. Zacks Research cut Arcutis Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, December 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research report on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $31.67.

Arcutis Biotherapeutics Stock Up 5.8%

Shares of ARQT opened at $28.57 on Thursday. The company has a 50-day simple moving average of $27.26 and a 200-day simple moving average of $23.71. The firm has a market capitalization of $3.50 billion, a P/E ratio of -204.06 and a beta of 1.70. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.28 and a current ratio of 3.50. Arcutis Biotherapeutics has a 52 week low of $11.86 and a 52 week high of $31.77.

Arcutis Biotherapeutics (NASDAQ:ARQT) last released its earnings results on Wednesday, February 25th. The company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.10. The business had revenue of $129.50 million for the quarter, compared to the consensus estimate of $110.79 million. Arcutis Biotherapeutics had a negative return on equity of 11.01% and a negative net margin of 4.29%. On average, equities research analysts expect that Arcutis Biotherapeutics will post -1.33 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Todd Watanabe sold 19,833 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $25.50, for a total transaction of $505,741.50. Following the sale, the insider owned 721,306 shares in the company, valued at approximately $18,393,303. This represents a 2.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Larry Todd Edwards sold 2,052 shares of Arcutis Biotherapeutics stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $25.50, for a total value of $52,326.00. Following the completion of the transaction, the insider directly owned 148,865 shares of the company’s stock, valued at $3,796,057.50. This represents a 1.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 124,656 shares of company stock valued at $3,312,365. Insiders own 9.40% of the company’s stock.

Institutional Trading of Arcutis Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. SBI Securities Co. Ltd. raised its position in Arcutis Biotherapeutics by 325.4% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,089 shares of the company’s stock worth $32,000 after purchasing an additional 833 shares during the last quarter. Global Retirement Partners LLC acquired a new stake in shares of Arcutis Biotherapeutics in the 4th quarter valued at $35,000. EverSource Wealth Advisors LLC raised its position in shares of Arcutis Biotherapeutics by 124.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company’s stock worth $37,000 after acquiring an additional 698 shares during the last quarter. NewEdge Advisors LLC lifted its stake in shares of Arcutis Biotherapeutics by 209.0% during the fourth quarter. NewEdge Advisors LLC now owns 1,545 shares of the company’s stock valued at $45,000 after acquiring an additional 1,045 shares during the period. Finally, Johnson Investment Counsel Inc. bought a new position in Arcutis Biotherapeutics in the third quarter valued at about $30,000.

Key Headlines Impacting Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Reported a robust Q4: ZORYVE product revenue of $127.5M (+84% YoY) and full‑year ZORYVE sales of $372.1M (+123% YoY); company raised 2026 net product sales guidance to $480–$495M — a clear driver of upward momentum. Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Beat EPS and revenue estimates: Q4 GAAP EPS $0.13 vs. consensus $0.03 and revenue ~$129.5M vs. $110.8M expected — the earnings beat and recurring revenue growth support a re-rating. ARQT Earnings Report
• Positive Sentiment: Clinical and regulatory catalyst: positive topline data in a Phase 2 infant trial for ZORYVE with an sNDA submission expected in Q2 2026 — potential label expansion that could meaningfully grow addressable market. Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Analyst upgrades: Needham raised its PT to $36 (buy) and TD Cowen raised its PT to $35 (buy), both implying >20% upside from current levels — these broker actions can drive buying interest. Needham Price Target Raise
• Positive Sentiment: Operational improvements: company produced positive operating cash flow in Q4 and expects to maintain positive operating cash flow quarterly going forward; also expanding dermatology sales and targeting primary care/pediatrics — supports sustainable commercialization. Business Update and Guidance
• Neutral Sentiment: Wall‑street commentary and analysis: bullish writeups (Seeking Alpha) highlight ZORYVE dominance and pipeline catalysts but note valuation is elevated (~9x forward EV/sales). Seeking Alpha Bull Case
• Neutral Sentiment: Marketing/awareness initiatives: consumer awareness campaign (celebrity partnership) may help demand over time but is not an immediate revenue driver. Marketing Campaign
• Neutral Sentiment: Short interest data reported is internally inconsistent (zeros/NaN) and provides no actionable signal. (Ignore until clearer filings are available.)
• Negative Sentiment: Profitability metrics remain mixed: company still showed negative net margin and negative ROE in some reports, and some analysts project a net loss (consensus -1.33 EPS for the year) — these fundamentals temper the upside and could limit multiple expansion if growth slows. ARQT Stock Summary

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.